ArticleMedical oncology (Northwood, London, England)2025
Bioengineered and biodegradable 3D scaffold for controlled drug delivery of 5-fluorouracil-loaded nanoparticle for bone tumor treatment.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main goal of the present was to develop an anticancer scaffold based on chitosan nanoparticles (CsNPs) loaded with 5-FU against bone tumor. The synthesized Cs/5-FU NPs were incorporated into an alginate hydrogel to obtain a functional scaffold. The results showed that the Cs/5-FU NPs have spherical morphology with a 112.3 ± 34.1 nm diameter and have a hydrodynamic size of around 321.0 ± 11.2 nm and the zeta potential of NPs was 31.4 ± 8.1 mV. SEM imaging showed that both hydrogels have a porous micro structure and the pores are interconnected and were biodegradable (lost around 70-85% of their initial weight during 28 days). The MTT assay showed that the Nanocomposite suppressed the cells growth and significantly induced anticancer cells effects, and significantly suppressed the migration/invasion potential of the cells. The intracellular Reactive Oxygen Species (ROS) measurement and mitochondrial membrane potential (ΔΨm) measurement assay showed that the Nanocomposite elevated the intracellular ROS and disrupted the ΔΨm, and subsequently induced apoptosis. The results indicate that the fabricated anticancer scaffold can be applied as an implantable scaffold for controlled and localized drug delivery of chemotherapeutic agents to bone tumor cells.
Indexed as
Identifiers
40736884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.